查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992497

雙胍類藥物市場：2026-2032年全球市場預測（按產品、劑型、釋放類型、劑量、分銷管道和最終用戶分類）

Biguanides Market by Product, Dosage Form, Release Type, Dosage Strength, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，雙胍類藥物市場價值將達到 58.2 億美元，到 2026 年將成長至 61.1 億美元，到 2032 年將達到 85.1 億美元，複合年成長率為 5.57%。

主要市場統計數據
基準年 2025 58.2億美元
預計年份：2026年 61.1億美元
預測年份 2032 85.1億美元
複合年成長率 (%) 5.57%

從策略角度展望化學品分類、臨床應用和商業性趨勢，以支援全球醫療保健系統的供應和取得。

雙胍類藥物在現代代謝性疾病管理中發揮核心作用，這得益於其長期的臨床應用和持續的治療價值。本執行摘要簡要概述了雙胍類藥物的化學分類、主流應用模式以及影響其生產、分銷和臨床說明的商業性趨勢。此外，本概要也整合了影響醫療機構供應和取得的監管考量、製劑趨勢以及相關人員的發展動態。

配方創新、供應鏈韌性、不斷變化的法規環境以及數位證據的流動如何重塑產品開發和商業化策略。

在多種變革力量的共同作用下，雙胍類藥物療法的格局正在發生變化，這些力量正在重塑產品的研發、生產和給藥方式。藥物科學的進步推動了人們對緩釋平台的興趣，因為緩釋平台可以提高病患的依從性和耐受性。同時，微劑量和顆粒劑型使得兒童和吞嚥困難的患者能夠更方便地用藥。同時，製藥公司正在重新審視其產品系列，以平衡自有品牌的創新與強大的非專利供給能力，這既反映了價格壓力，也反映了處方醫生對安全性已得到驗證的藥物的偏好。

美國新的關稅措施鼓勵策略性地域多角化和整個價值鏈的合約保護，這將對供應鏈、採購和購買產生連鎖反應。

美國2025年實施的關稅措施對整個雙胍類藥物價值鏈產生了多層次的影響，其影響遠不止於表面的價格波動，也涵蓋了籌資策略、製造地和庫存管理等各個方面。由於關稅導致進口原料藥（ API）和中間體的接收成本增加，促使垂直整合的生產商和契約製造生產商重新評估其供應商基礎，加速了關於原料藥生產地域多角化以及選擇符合嚴格品質和監管標準的替代供應商的討論。

以細分市場主導的觀點，將產品類型、配方、上市策略、劑量選擇、通路和最終用戶需求與可行的商業性優先事項聯繫起來。

基於細分市場的洞察對於理解雙胍類藥物的競爭動態和患者治療路徑至關重要。從產品分類的角度來看，品牌藥和非專利藥之間有明顯的差異。品牌藥通常強調差異化的臨床訊息和生命週期管理，而非專利突顯成本效益和大規模生產能力。劑型細分市場凸顯了顆粒劑和粉劑在特定給藥場景和吞嚥困難患者群體中的重要性，而片劑仍然是門診病人廣泛使用的主要劑型。

決定全球市場監管合規性、籌資策略、製造地選擇和分銷管道最佳化的區域因素。

區域因素對生產者、經銷商和醫療系統處理雙胍類藥物的策略有顯著影響。在美洲，監管協調和成熟的供應鏈網路支援產品快速上市和多元化的分銷管道，但該地區也面臨著支付方主導的成本控制壓力，導致學名藥的推廣和基於價值的合約日益受到重視。歐洲、中東和非洲（EMEA）地區的監管和報銷環境各不相同，藥物取得和採購趨勢也存在顯著差異。生產商通常採用差異化定價和選擇性夥伴關係，以適應公共採購模式和私立醫院網路，同時還要在複雜的物流路線中管理品管和假冒風險。

在該治療領域，生產規模、合約夥伴關係、製劑技術和分銷彈性如何決定競爭地位和供應可靠性？

雙胍類藥物生態系統中的主要企業透過整合生產規模、智慧財產權、生命週期管理以及下游服務能力來脫穎而出。領先的先驅企業利用已建立的臨床信任和監管資本，支持緩釋製劑的創新和適應症的拓展，而契約製造和非專利製造商則在單位成本、供應可靠性和快速生產規模化能力方面展開競爭。先驅企業與契約製造製造商之間的策略合作夥伴關係日益普遍，這種合作模式能夠實現靈活的生產結構和風險共擔機制，從而確保供應的連續性。

在政策和採購環境持續不確定性的情況下，正在採取實際措施，幫助製造商和經銷商提高供應連續性、商業性差異化和與支付方的互動。

面對不斷變化的挑戰，產業領導企業應採取切實可行且優先的措施，以保護利潤率、確保供應並支持臨床應用。首先，實現原料藥和製劑來源多元化，減少對單一供應商的依賴，並對位於符合監管標準且能夠快速擴大產能地區的供應商進行認證。其次，投資於能夠提高用藥依從性和耐受性的製劑平台（特別是緩釋製劑和患者友善劑型），以實現超越價格競爭的臨床差異化。第三，透過根據醫院採購標準、網路藥局合規要求和零售藥房需求客製化產品供應和契約，並針對每個銷售管道最佳化包裝、標籤和患者支援材料，來強化銷售管道策略。

我們採用混合證據框架，結合相關人員訪談、監管和臨床文件、供應鏈圖譜和情境分析，以得出可操作的結論。

本執行摘要的研究採用了混合研究方法，以確保提供平衡且基於證據的見解。主要研究包括對供應鏈經理、處方集決策者、醫院藥局主任和生產負責人進行結構化訪談，以了解營運實際情況和策略重點。次要研究則納入了監管文件、產品標籤資料、專利註冊資訊、臨床文獻和公共採購文件，以檢驗結構性趨勢並將其反映在細分定義中。

統一的結論強調，維持競爭優勢需要整合產品差異化、供應鏈韌性和通路特定的商業化策略。

綜合分析表明，在雙胍類藥物市場中保持競爭優勢需要整體性策略，以平衡產品差異化、供應鏈韌性和市場特定的商業化策略。配方和品質保證的技術投資可促進臨床應用並降低風險，而採購和製造地的多元化則可減少關稅和地緣政治因素造成的干擾。針對特定管道的策略以及針對細分市場的包裝和支援服務有助於在醫院、線上和零售管道推廣應用，而與支付方和醫療服務提供者開展基於真實世界數據的合作則有助於保障報銷權益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 雙胍類藥物市場：依產品分類

  • 品牌商品
  • 非專利的

第9章 雙胍類藥物市場（依劑型分類）

  • 顆粒
  • 粉末
  • 藥片

第10章：雙胍類藥物市場釋放類型

  • 緩釋
  • 立即發布

第11章 雙胍類藥物市場（按劑量分類）

  • 1000 mg
  • 500 mg
  • 850 mg

第12章 雙胍市場：按分銷管道分類

  • 線上
  • 離線

第13章 雙胍市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第14章 雙胍市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：雙胍類藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 雙胍市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國雙胍類藥物市場

第18章：中國雙胍市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Granules India Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Upsher-Smith Laboratories, LLC
  • USV Private Limited
  • Viatris Inc.（formerly Mylan）
  • Zydus Lifesciences Limited
Product Code: MRR-3204321AF9EA

The Biguanides Market was valued at USD 5.82 billion in 2025 and is projected to grow to USD 6.11 billion in 2026, with a CAGR of 5.57%, reaching USD 8.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.82 billion
Estimated Year [2026] USD 6.11 billion
Forecast Year [2032] USD 8.51 billion
CAGR (%) 5.57%

A strategic orientation to the chemical class, clinical usage, and commercial dynamics that underpin availability and access across global healthcare systems

The biguanide category occupies a central role in contemporary metabolic disease management, driven by longstanding clinical adoption and continued therapeutic relevance. This executive summary presents a concise orientation to the chemical class, prevailing usage paradigms, and the commercial dynamics that influence manufacturing, distribution, and clinical deployment. It synthesizes regulatory considerations, formulation trends, and stakeholder behaviors that shape availability and access across care settings.

Readers will find a clear delineation between brand and generic channels, formulation choices from granules and powders to conventional tablets, and the implications of immediate versus extended release technologies. The summary also situates dosing strengths commonly encountered in therapeutic protocols and outlines the primary distribution pathways through hospital, online, and retail pharmacies. By integrating clinical practice realities with supply chain constraints and policy shifts, this introduction primes decision-makers for the deeper analyses that follow, enabling rapid alignment of product development, procurement, and market access strategies without relying on volumetric projections.

How formulation innovation, supply chain resilience, and evolving regulatory and digital evidence streams are reshaping product development and commercialization strategies

The landscape for biguanide therapies is evolving under several convergent transformational forces that are reshaping how products are developed, manufactured, and delivered to patients. Advances in formulation science have elevated interest in extended release platforms that can improve adherence and tolerability, while microdosing and granule formats enable pediatric and dysphagia-friendly administration. Simultaneously, manufacturers are recalibrating portfolios to balance branded innovation with robust generic supply capabilities, reflecting both pricing pressures and prescriber preferences for established safety profiles.

Digital health integration and real-world evidence generation are enabling prescribers and payers to refine utilization and outcomes measurement, which in turn influences procurement decisions at hospital systems and payer networks. At the same time, heightened attention to supply chain resilience has prompted strategic sourcing and redundant manufacturing relationships, encouraging investments in regional API production and quality assurance programs. Regulatory frameworks are also progressing to accommodate lifecycle management for established compounds, permitting label enhancements and new formulation approvals where clinical differentiation is demonstrated. Together, these shifts favor agile manufacturers who can pair technical formulation competencies with downstream commercialization and distribution strategies that address diverse care settings and patient needs.

The cascading supply chain, sourcing, and procurement consequences of new United States tariff measures that are prompting strategic regionalization and contractual protections across the value chain

The introduction of United States tariff measures in 2025 has created layered implications across the biguanide value chain that extend beyond headline pricing effects to influence sourcing strategies, manufacturing footprints, and inventory management. Tariff-driven increases in the landed cost of imported active pharmaceutical ingredients and intermediates encourage vertically integrated producers and contract manufacturers to reassess their supplier base, accelerating conversations about regionalization of API production and qualification of alternative suppliers that meet stringent quality and regulatory criteria.

Healthcare procurement teams and distribution partners are adapting by increasing buffer inventories for critical finished-dose products while refining demand planning to reduce exposure to border-related volatility. Parallel to sourcing adjustments, some manufacturers are exploring reformulation or packaging efficiencies that mitigate per-unit cost increases without compromising clinical performance. Payers and large purchasers are pressuring suppliers for greater transparency on cost drivers, prompting more rigorous cost-of-goods analyses and value-based contracting discussions that reflect total cost implications rather than simple price movements. In aggregate, tariffs act as a catalyst for structural changes in supply relationships, prompting a shift toward supply chain agility, diversified manufacturing bases, and stronger contractual protections against trade-related disruptions.

A segmentation-led perspective linking product type, formulation, release strategy, strength options, distribution pathways, and end-user demands to actionable commercial priorities

Segmentation-driven insight is essential to understanding competitive dynamics and patient pathways in the biguanide category. When viewed through the lens of product classification, clear distinctions emerge between brand and generic offerings, with branded products typically commanding differentiated clinical messaging and lifecycle management efforts while generics emphasize cost efficiency and scale manufacturing capabilities. Dosage form segmentation highlights the importance of granules and powders for specialized administration scenarios and populations with swallowing difficulties, whereas tablets remain the primary vehicle for broad outpatient adherence.

Release type segmentation delineates commercial positioning and clinical utility, as extended release formulations are often pursued to improve tolerability and adherence compared with immediate release options, influencing prescribing patterns and formulary placement. Dosage strength segmentation-commonly centered on 1000 mg, 500 mg, and 850 mg options-shapes inventory strategies and prescribing convenience, with manufacturers and distributors ensuring strength availability to accommodate titration protocols. Distribution channel segmentation underscores divergent procurement and dispensing models: hospital pharmacies in both private and public systems prioritize institutional contracts and stocking policies; online channels including e-pharmacy platforms and manufacturer direct models emphasize convenience and patient access; retail pharmacies comprised of chain and independent operators focus on point-of-care counseling and community dispensing. End-user segmentation across clinics, home care settings, and hospitals affects product packaging, patient education materials, and logistics, as each setting presents unique storage, administration, and adherence support requirements. Understanding performance across each segment enables targeted investments in formulation, channel partnerships, and service offerings that match clinician workflows and patient preferences.

Regional considerations that determine regulatory navigation, procurement strategies, manufacturing placement, and distribution channel optimization across global markets

Regional considerations materially influence strategy for manufacturers, distributors, and health systems operating with biguanide therapies. In the Americas, regulatory harmonization and mature supply networks support rapid product launches and diversified distribution channels, yet the region also faces payer-driven cost containment pressures that emphasize generic adoption and value-based contracting. Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement environment where access and purchasing dynamics vary widely; manufacturers often deploy differentiated pricing approaches and selective partnerships to navigate public procurement models and private hospital networks while managing quality and counterfeiting risks across complex logistics routes.

Asia-Pacific continues to be defined by a mix of highly capable local manufacturers and strong demand growth in both urban and rural healthcare settings. The region's manufacturing capacities for APIs and finished dosage forms offer strategic advantages for global sourcing, yet localization policies and variable regulatory convergence require nuanced market entry and supply strategies. Across all regions, distribution channel maturity, digital marketplace adoption, and public health priorities shape the commercial calculus, prompting actors to align product offerings and service models with regional clinical practice, payer expectations, and infrastructure realities.

How manufacturer scale, contract partnerships, formulation expertise, and distribution agility are defining competitive positioning and supply reliability in the therapeutic class

Key corporate actors in the biguanide ecosystem are differentiating through a mix of manufacturing scale, intellectual property and lifecycle management, and downstream service capabilities. Larger originator companies leverage established clinical trust and regulatory capital to support extended release innovations and label expansions, while contract manufacturing organizations and generic producers compete on unit cost, supply reliability, and rapid scale-up capabilities. Strategic partnerships between originators and contract manufacturers are increasingly common, enabling flexible production and risk-sharing arrangements that protect supply continuity.

Across the competitive set, investment priorities coalesce around quality assurance systems, regulatory compliance infrastructure, and digital tooling for pharmacovigilance and adherence support. Companies that combine deep formulation expertise with robust quality management and geographically diversified manufacturing networks are better positioned to meet procurement requirements and respond to policy shifts. In addition, organizations that actively manage distribution partnerships, direct-to-patient channels, and institutional contracting demonstrate greater resilience amid procurement pressure and supply disruptions. Finally, corporate strategies that incorporate sustainability measures and transparent supplier audits are gaining traction with institutional buyers who prioritize long-term supply security and reputational risk management.

Practical steps for manufacturers and distributors to strengthen supply continuity, commercial differentiation, and payer engagement under persistent policy and sourcing uncertainties

Industry leaders should adopt a set of pragmatic, prioritized actions to protect margins, secure supply, and support clinical adoption in the face of evolving headwinds. First, diversify API and finished-dose sourcing to reduce single-source exposure and qualify regionally located suppliers that meet regulatory standards and can ramp capacity quickly. Second, invest in formulation platforms that address adherence and tolerability-particularly extended release and patient-friendly dosage forms-to create clinical differentiation beyond price-based competition. Third, strengthen commercial channel strategies by tailoring offerings and contracting to hospital procurement norms, e-pharmacy compliance requirements, and retail pharmacy needs, ensuring packaging, labeling, and patient support materials are optimized for each route to market.

Further, incorporate robust scenario planning that models tariff impacts, regulatory shifts, and supply interruptions, and use those scenarios to negotiate flexible supply agreements and protective clauses. Enhance collaboration with payer and provider stakeholders by sharing real-world evidence that underscores therapeutic value and supports favorable formulary placement. Finally, prioritize investments in quality systems, supplier audits, and sustainability initiatives to meet increasingly rigorous procurement standards and to build trust with large institutional buyers.

A mixed-methods evidence framework combining stakeholder interviews, regulatory and clinical documentation, supply chain mapping, and scenario analysis to underpin actionable conclusions

The research underpinning this executive summary employed a mixed-methods approach to ensure balanced, evidence-based insights. Primary research included structured interviews with supply chain managers, formulary decision-makers, hospital pharmacy directors, and manufacturing leaders to capture operational realities and strategic priorities. Secondary analysis incorporated regulatory filings, product labeling data, patent registries, clinical literature, and public procurement documentation to validate structural trends and inform segmentation definitions.

Data were triangulated across sources to reconcile discrepancies and to identify persistent patterns in formulation choices, distribution behaviors, and regional regulatory practices. Analytical methods included supply chain mapping to assess exposure to trade and tariff risks, qualitative thematic analysis of stakeholder interviews to surface decision drivers, and scenario-based risk assessment to evaluate potential operational responses. Findings were peer-reviewed by external subject-matter experts and validated against documented regulatory and clinical guidance to ensure relevance and accuracy for commercial decision-makers.

Consolidated conclusions emphasizing the need for integrated product differentiation, supply chain resilience, and channel-specific commercialization strategies to sustain advantage

The consolidated analysis highlights that sustaining competitive advantage in the biguanide space will depend on an integrated approach that balances product-level differentiation, supply chain resilience, and market-specific commercialization strategies. Technical investments in formulation and quality assurance support clinical adoption and mitigate risk, while diversified sourcing and manufacturing footprints reduce exposure to tariff-driven and geopolitical disruptions. Channel-specific tactics and segment-aligned packaging and support services improve uptake across hospital, online, and retail pathways, while engagement with payers and providers based on real-world evidence can protect reimbursement positioning.

In short, resilient, customer-centric operational models that leverage formulation innovation, strategic partnerships, and rigorous supplier governance are the most effective ways to navigate current and emerging challenges. Decision-makers who align R&D, procurement, and commercial activities around these priorities will be better positioned to maintain supply reliability, preserve margins, and meet the evolving needs of clinicians and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biguanides Market, by Product

  • 8.1. Brand
  • 8.2. Generic

9. Biguanides Market, by Dosage Form

  • 9.1. Granule
  • 9.2. Powder
  • 9.3. Tablet

10. Biguanides Market, by Release Type

  • 10.1. Extended Release
  • 10.2. Immediate Release

11. Biguanides Market, by Dosage Strength

  • 11.1. 1000 Mg
  • 11.2. 500 Mg
  • 11.3. 850 Mg

12. Biguanides Market, by Distribution Channel

  • 12.1. Online
  • 12.2. Offline

13. Biguanides Market, by End User

  • 13.1. Clinic
  • 13.2. Home Care
  • 13.3. Hospital

14. Biguanides Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biguanides Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biguanides Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Biguanides Market

18. China Biguanides Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AstraZeneca plc
  • 19.6. Bayer AG
  • 19.7. Biocon Limited
  • 19.8. Boehringer Ingelheim
  • 19.9. Bristol Myers Squibb
  • 19.10. Cipla Limited
  • 19.11. Dr. Reddy's Laboratories Limited
  • 19.12. Eli Lilly and Company
  • 19.13. GlaxoSmithKline plc
  • 19.14. Glenmark Pharmaceuticals Limited
  • 19.15. Granules India Limited
  • 19.16. Johnson & Johnson
  • 19.17. Lupin Limited
  • 19.18. Merck & Co., Inc.
  • 19.19. Novartis AG
  • 19.20. Novo Nordisk A/S
  • 19.21. Pfizer Inc.
  • 19.22. Sanofi
  • 19.23. Sun Pharmaceutical Industries Limited
  • 19.24. Takeda Pharmaceutical Company Limited
  • 19.25. Teva Pharmaceutical Industries Limited
  • 19.26. Upsher-Smith Laboratories, LLC
  • 19.27. USV Private Limited
  • 19.28. Viatris Inc. (formerly Mylan)
  • 19.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIGUANIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIGUANIDES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIGUANIDES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIGUANIDES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIGUANIDES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIGUANIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIGUANIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIGUANIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIGUANIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIGUANIDES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIGUANIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIGUANIDES MARKET SIZE, BY BRAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIGUANIDES MARKET SIZE, BY BRAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIGUANIDES MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIGUANIDES MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIGUANIDES MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIGUANIDES MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIGUANIDES MARKET SIZE, BY GRANULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIGUANIDES MARKET SIZE, BY GRANULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIGUANIDES MARKET SIZE, BY GRANULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIGUANIDES MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIGUANIDES MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIGUANIDES MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIGUANIDES MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIGUANIDES MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIGUANIDES MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIGUANIDES MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIGUANIDES MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIGUANIDES MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIGUANIDES MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIGUANIDES MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIGUANIDES MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIGUANIDES MARKET SIZE, BY 1000 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIGUANIDES MARKET SIZE, BY 1000 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIGUANIDES MARKET SIZE, BY 1000 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIGUANIDES MARKET SIZE, BY 500 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIGUANIDES MARKET SIZE, BY 500 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIGUANIDES MARKET SIZE, BY 500 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIGUANIDES MARKET SIZE, BY 850 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIGUANIDES MARKET SIZE, BY 850 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIGUANIDES MARKET SIZE, BY 850 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIGUANIDES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIGUANIDES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIGUANIDES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIGUANIDES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIGUANIDES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIGUANIDES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIGUANIDES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIGUANIDES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIGUANIDES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIGUANIDES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIGUANIDES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIGUANIDES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIGUANIDES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIGUANIDES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIGUANIDES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIGUANIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS BIGUANIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIGUANIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. GCC BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 121. GCC BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 123. GCC BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 141. G7 BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. G7 BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. G7 BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 144. G7 BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. NATO BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 149. NATO BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NATO BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 151. NATO BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIGUANIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES BIGUANIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA BIGUANIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA BIGUANIDES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA BIGUANIDES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA BIGUANIDES MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA BIGUANIDES MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA BIGUANIDES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA BIGUANIDES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)